Search Results
Your search for Chase Doyle matches 567 pages
Showing 101 - 150Acupuncture May Improve Sleep Among Patients With Multiple Myeloma Undergoing HSCT
An ancient practice may offer modern relief for sleep disturbances experienced by patients with multiple myeloma undergoing hematopoietic stem cell transplant (HSCT), according to research published by El Iskandarani et al in Acupuncture in Medicine. Based on a randomized, prospective study of 63...
CLL14: Long-Term Results of Fixed-Duration Venetoclax Plus Obinutuzumab in Elderly Patients With CLL
The 6-year follow-up of a landmark study has revealed significant treatment-free remissions and safety findings in elderly patients with chronic lymphocytic leukemia (CLL) and coexisting medical conditions.1 Long-term results of the CLL14 trial, presented during the European Hematology Association...
Expert Point of View: Gustavo Werutsky, MD and Lisa A. Carey, MD, ScM, FASCO
Invited discussant Gustavo Werutsky, MD, emphasized that health-related quality of life was consistently maintained in all phase III trials with fam-trastuzumab deruxtecan-nxki (T-DXd) in the metastatic breast cancer setting. Dr. Werutsky also highlighted the need for real-world data to understand...
Two Studies Highlight Benefits in Quality of Life and Symptom Management With Novel Treatments of Advanced Breast Cancer
Recent improvements in overall and progression-free survival for patients with HER2-positive and estrogen receptor–positive breast cancers have not come at the expense of quality of life or symptom management, according to a pair of studies presented at the European Society for Medical Oncology...
Pathology Assessment During Mastectomy and Overtreatment of the Axilla in Clinically Node-Negative Breast Cancer
Axillary management decisions made during surgery may be associated with aggressive treatment of limited nodal disease, according to data presented at a press briefing at the 2023 American Society of Breast Surgeons Annual Meeting.1 Results of a large National Cancer Database study revealed that...
Thinking Outside the Box: Embracing Innovation and Collaboration in Oncology
In the ever-evolving landscape of oncology care, embracing innovation and creative problem-solving have become crucial factors for success. At the 2023 Community Oncology Alliance Annual Meeting, a panel discussion tackled the complexities and opportunities associated with implementing value-based...
Building a More Equitable Oncology Practice: The Path to Better Patient Outcomes
By embracing diversity, equity, and inclusion (DEI), oncology practices can work toward better patient outcomes and a more effective health-care system, according to Richard L. Martin III, MD, MPH, Medical Director of Health Equity and Community Engagement at Tennessee Oncology. At the 2023...
Study Finds Preoperative MRI Does Not Significantly Impact Margin Status in Patients With Breast Cancer
The use of preoperative magnetic resonance imaging (MRI) did not significantly reduce positive margins after breast-conserving surgery, according to data presented during a press briefing at the 2023 American Society of Breast Surgeons Annual Meeting.1 Although MRI has been shown to detect...
Expert Point of View: Loren Laine, MD
Abstract discussant, Loren Laine, MD, Digestive Disease Week Council Chair and Professor of Medicine, Digestive Diseases, at Yale School of Medicine, acknowledged the clear link between obesity and various types of cancer and noted it logically follows that weight loss may help to reduce this risk. ...
Can Bariatric Surgery Decrease the Risk of Obesity-Related Cancers?
A new study presented at Digestive Disease Week 2023 has shown that just 4% of patients with obesity who underwent bariatric surgery developed obesity-associated cancer in a 10-year follow-up, compared with 8.9% among those who did not have a weight-loss procedure.1 These findings indicate that the ...
Expert Point of View: Matteo Lambertini, MD, PhD
Invited discussant of these two trials, Matteo Lambertini, MD, PhD, Associate Professor at the University of Genova–IRCCS Policlinico San Martino Hospital Genoa, Italy, emphasized the importance of longer follow-up periods for both these clinical trials and the need to wait for the additional...
Two Studies of Atezolizumab-Based Regimens in Early-Stage, Triple-Negative and HER2-Positive Breast Cancers
Immunotherapy regimens involving the PD-L1 monoclonal antibody atezolizumab have demonstrated promising results in patients with early-stage, triple-negative breast cancer and HER2-positive breast cancer, according to a pair of studies presented at the European Society for Medical Oncology (ESMO)...
Expert Point of View: Tina Cascone, MD, PhD
Discussant of the Neotorch study abstract, Tina Cascone, MD, PhD, of the Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, commended the authors for completing the initial analysis of the phase III randomized Neotorch trial, which...
Toripalimab Plus Chemotherapy Improves Event-Free Survival in Resectable Stage III NSCLC
Findings from a phase III, randomized trial highlight the benefit derived from perioperative immunotherapy in patients with early-stage resectable non–small cell lung cancer (NSCLC), according to data presented during the ASCO Plenary Series: April 2023 Session.1 Interim analysis of the Neotorch...
Expert Point of View: Rebecca A. Dent, MD, MSc
Invited discussant Rebecca A. Dent, MD, MSc, Senior Consultant, National Cancer Center Singapore, and Chairman of Medical Oncology at Duke-NUS Medical School, called the findings from these studies “very promising” and “provocative” but acknowledged that the small number of patients precludes...
HER3-Targeting Antibody-Drug Conjugates Show Encouraging Results in Breast Cancer Subtypes
Early-phase data from the SOLTI TOT-HER3 and ICARUS-BREAST01 trials suggest that the novel HER3-directed antibody-drug conjugate patritumab deruxtecan may have beneficial activity in patients with hormone receptor–positive/HER2-negative and triple-negative breast cancer subtypes, according to...
Immune Checkpoint Inhibitors Show Promise for People Living With HIV
New research involving people living with HIV treated with immune checkpoint inhibitors has provided valuable insights into the safety and efficacy of immunotherapy in this historically excluded population, according to data published by El Zarif et al in the Journal of Clinical Oncology. The...
Expert Point of View: Jarushka Naidoo, MBBCh, MHS
Invited discussant Jarushka Naidoo, MBBCh, MHS, Professor of Medical Oncology and Consultant Medical Oncologist, Beaumont RCSI Cancer Centre, in Dublin, called the results of amivantamab-vmjw therapy in patients with EGFR exon 20 insertion–positive advanced non–small cell lung cancer (NSCLC)...
Amivantamab Shows Efficacy in Advanced NSCLC With EGFR Exon 20 Insertions
Amivantamab-vmjw, an EGFR and MET bispecific monoclonal antibody, has demonstrated encouraging long-term benefits and consistent efficacy in patients with advanced non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions, according to data presented by Pilar Garrido, MD, PhD, Associate...
Expert Point of View: Daniel SW Tan, BSc, MBBS, PhD
Invited discussant of the phase II APPLE trial, Daniel SW Tan, BSc, MBBS, PhD, of the National Cancer Centre Singapore, noted that 17% of patients have had only molecular disease progression and were switched over to the sequential strategy. “This may be in some parts related to the sensitivity of...
Front-Line vs Sequential Use of Osimertinib in EGFR-Mutant NSCLC: Potential Impact of Liquid Biopsies
Using liquid biopsies to detect circulating tumor DNA (ctDNA) may soon transform treatment strategies for patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC), according to data presented during the European Lung Cancer Congress 2023 by lead study author Jordi Remon, MD, PhD, of...
Expert Point of View: Antonio Passaro, MD, PhD
Invited discussant Antonio Passaro, MD, PhD, of the European Institute of Oncology, Milan, Italy, underscored the significant results of the landmark CheckMate 816 trial, which he said, “established a new treatment paradigm for resectable NSCLC [non–small cell lung cancer].” In addition to the 14% ...
CheckMate 816: 3-Year Update Shows Improved Event-Free Survival With Neoadjuvant Nivolumab and Chemotherapy for Resectable NSCLC
The combination of neoadjuvant nivolumab plus chemotherapy continues to demonstrate potential as a standard treatment for patients with resectable non–small cell lung cancer (NSCLC), according to data presented during the European Lung Cancer Congress 2023.1 The 3-year update from the phase III...
Expert Point of View: Jarushka Naidoo, MBBCh, MHS
The invited discussant for the CodeBreaK 200 trial, Jarushka Naidoo, MBBCh, MHS, Professor of Medical Oncology and Consultant Medical Oncologist at Beaumont RCSI Cancer Centre in Dublin, underscored the importance of patient-reported outcomes in evaluating the effectiveness of oncology treatments,...
CodeBreaK 200: Sotorasib Offers Improved Quality of Life for Patients With Previously Treated NSCLC
The latest research on sotorasib, a targeted therapy for KRAS G12C–mutated non–small cell lung cancer (NSCLC), reveals that patients may experience better quality of life while benefiting from improved clinical outcomes. Analysis of patient-reported outcomes presented during the European Lung...
Expert Point of View: Jaffer A. Ajani, MD
Jaffer A. Ajani, MD, Professor of Medicine in the Department of Gastrointestinal Oncology at The University of Texas MD Anderson Cancer Center, told The ASCO Post that obesity (defined as high body mass index of 30–39.9 kg/m2) is increasing around the globe; by 2035, more than 50% of adults will...
Study Reveals Link Between Obesity and Gastric Cancer Aggressiveness
A pioneering study from Israel has shed new light on the link between obesity and the aggressiveness of gastric cancer while demonstrating potential therapeutic targets for the disease. Results of the translational research, presented during the Society of Surgical Oncology (SSO) 2023 International ...
Expert Point of View: Callisia N. Clarke, MD, MS, FACS, FSSO
Moderator of the press conference at the 2023 Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care, Callisia N. Clarke, MD, MS, FACS, FSSO, Assistant Professor of Surgery, Medical College of Wisconsin, shared insights on the transition of circulating tumor DNA...
Using Circulating Tumor DNA to Predict Early Recurrence of Soft-Tissue Sarcomas
Circulating tumor DNA (ctDNA) may transform disease monitoring and guide treatment for soft-tissue sarcomas, according to data presented at the 2023 Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care.1 Findings of a retrospective review showed that 85% of patients...
Toripalimab Plus Chemotherapy May Improve Event-Free Survival in Resectable Stage III NSCLC
An interim analysis of the Neotorch study highlighted the potential of immunotherapy for the treatment of early-stage non–small cell lung cancer (NSCLC), according to data presented by Lu et al during the ASCO Plenary Series: April 2023 Session (Abstract 425126). The findings showed a significant...
Expert Point of View: Callisia N. Clarke, MD, MS, FACS, FSSO
Moderator of the press conference at the 2023 International Conference on Surgical Cancer Care, Callisia N. Clarke, MD, MS, FACS, FSSO, Assistant Professor of Surgery at the Medical College of Wisconsin, highlighted the significance of the 80% response rates to neoadjuvant immunotherapy in primary...
Neoadjuvant Pembrolizumab in Desmoplastic Melanoma
Neoadjuvant pembrolizumab may significantly improve the management of desmoplastic melanoma, increasing the likelihood of successful resection and reducing the need for further surgery or radiation therapy, according to the response data presented at the 2022 ASCO Annual Meeting, with the surgical...
RUBY Trial: Dostarlimab Plus Carboplatin and Paclitaxel in Advanced Endometrial Cancer
Adding immunotherapy to standard chemotherapy for the first-line treatment of advanced or the first recurrence of endometrial cancer significantly improved progression-free survival compared to chemotherapy alone, according to data presented by Mansoor Raza Mirza, MD, and colleagues at the March...
Expert Point of View: Anjali S. Advani, MD
Discussant of the February ASCO Plenary session, Anjali S. Advani, MD, Staff Physician in the Department of Hematologic Oncology and Blood Disorders and Director of the Inpatient Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, noted that the PhALLCON study is the only prospective...
PhALLCON Study: Ponatinib Superior to Imatinib in Combination With Chemotherapy in Newly Diagnosed, Ph-Positive ALL
Ponatinib appears to be a more effective tyrosine kinase inhibitor than imatinib in newly diagnosed, Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) when combined with reduced-intensity chemotherapy, according to data presented during the ASCO Plenary Series: February 2023...
Expert Point of View: Breelyn A. Wilky, MD
Discussant of the INTRIGUE abstract, Breelyn A. Wilky, MD, Director of Sarcoma Medical Oncology, Deputy Associate Director for Clinical Research, University of Colorado, Aurora, called the data presented “compelling evidence of the power of ctDNA [circulating tumor DNA] to identify predictive...
INTRIGUE Study: Circulating Tumor DNA Analysis May Predict Optimal Treatment of Patients With GIST
Circulating tumor DNA (ctDNA) analysis of KIT exon mutations may help to predict which second-line therapy is best for patients with advanced gastrointestinal stromal tumor (GIST), according to data presented during the ASCO Plenary Series: January 2023 Session.1 Exploratory analysis of the phase...
Expert Point of View: Bita Fakhri, MD, MPH
Moderator of the session on the CLL2-GIVe regimen, Bita Fakhri, MD, MPH, Assistant Professor of Medicine at Stanford Medicine, California, said that findings from the ongoing, phase III CLL13 trial will ultimately determine which regimen is appropriate for patients with high-risk chronic...
CLL2-GIVe Trial: Regimen of Obinutuzumab, Ibrutinib, and Venetoclax Effective in High-Risk CLL
The first-line combination of obinutuzumab, ibrutinib, and venetoclax appears to be effective in treating high-risk chronic lymphocytic leukemia (CLL), according to data presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.1 Results of the CLL2-GIVe trial, which...
Expert Point of View: Catherine S. Diefenbach, MD
Catherine S. Diefenbach, MD, Associate Professor at NYU Grossman School of Medicine, Director of the Clinical Lymphoma Program, and Director of Hematology Translational Research at Perlmutter Cancer Center, in New York, called the findings from the TRANSFORM trial “very striking.” “This study...
CAR T-Cell Therapy vs Chemoimmunotherapy in Second-Line Treatment of Resistant Large B-Cell Lymphoma
New research has confirmed the superiority of lisocabtagene maraleucel over the standard of care for the second-line treatment of primary refractory or early relapsed large B-cell lymphoma, according to data presented by lead study author Jeremy S. Abramson, MD, Associate Professor of Medicine at...
Quick Takes on Important Cancer Research From ASH 2022
The high-energy vibe at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition reflected the welcomed presence of enthusiastic on-site attendees and the high quality of the research presented. The ASCO Post has already reported in detail on many of these presentations, and now...
Expert Point of View: Catherine S. Diefenbach, MD
Catherine S. Diefenbach, MD, Associate Professor at NYU Grossman School of Medicine, Director of the Clinical Lymphoma Program, and Director of Hematology Translational Research at Perlmutter Cancer Center, in New York, called the findings from the TRANSFORM trial “very striking.” “This study...
CAR T-Cell Therapy vs Chemoimmunotherapy in Second-Line Treatment of Resistant Large B-Cell Lymphoma
New research has confirmed the superiority of lisocabtagene maraleucel over the standard of care for the second-line treatment of primary refractory or early relapsed large B-cell lymphoma, according to data presented by lead study author Jeremy S. Abramson, MD, Associate Professor of Medicine at...
Expert Point of View: Emily K. Curran, MD
Moderator of the session, Emily K. Curran, MD, Assistant Professor of Internal Medicine at the University of Cincinnati Cancer Center, in Ohio, said that the data presented by Dr. Short and colleagues demonstrated very impressive event-free and overall survival rates, especially for a disease that...
Ponatinib and Blinatumomab Combination Safe and Effective in Patients With Newly Diagnosed, Ph-Positive ALL
The combination of ponatinib and blinatumomab has led to rapid and durable remissions in patients with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), according to data presented at the 2022 American Society of Hematology (ASH) Annual Meeting and...
ctDNA Analysis May Predict Optimal Treatment for Patients With GIST
Circulating tumor DNA (ctDNA) analysis of KIT exon mutations may help predict which second-line therapy is best for patients with advanced gastrointestinal stromal tumor (GIST), according to data presented by Bauer et al during the January ASCO Plenary Series session (Abstract 397784). An...
Expert Point of View: Antonio González-Martín, MD, PhD
Abstract discussant of the NORA trial, Antonio González-Martín, MD, PhD, Director of the Department of Medical Oncology at Clinica Universidad de Navarra, Madrid, said that despite the results of this ad hoc interim analysis, “the jury is still out” regarding the overall survival benefit of PARP...
Phase III NORA Trial: Niraparib Maintenance Shows Overall Survival Trend in Platinum-Sensitive Recurrent Ovarian Cancer
Maintenance therapy with a poly (ADP-ribose) polymerase (PARP) inhibitor may do more than just delay disease progression for patients with platinum-sensitive, relapsed ovarian cancer; it might also improve overall survival, according to data presented during the December 2022 European Society for...
Expert Point of View: Bita Fakhri, MD, MPH
Moderator of the session on the CLL2-GIVe regimen, Bita Fakhri, MD, MPH, Assistant Professor of Medicine at Stanford Medicine, California, said that findings from the ongoing, phase III CLL13 trial will ultimately determine which regimen is appropriate for patients with high-risk chronic...
